首页> 美国卫生研究院文献>Asian Pacific Journal of Cancer Prevention : APJCP >Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients
【2h】

Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients

机译:BRCA1 vs. BRCA2突变家族的差异概况:患者主要差异和相似性的表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The identification of families at-risk for hereditary breast cancer (BC) is important because affected individuals present a much higher cancer risk than the general population. The aim of this study was to identify the most important factors associated with the presence of a pathogenic mutation. Family history (FH), histopathological and immunohistochemical characteristics were compared among BC women with pathogenic variants; VUSs in B ; and sporadic BC. The most significative differences observed concerned the molecular subtype of the tumors, age at cancer diagnosis and FH of cancer. The presence of bilateral breast cancer (BBC), number of BC cases and the presence of ovarian cancer (OC) increased (respectively) 5.797, 5.033 and 4.412 times the risk of being a mutation carrier. Besides, women with or mutations presented different tumor and FH profiles. The main characteristics associated with a mutation were triple negativity (OR: 17.31), BBC history (OR: 4.96) and occurrence of OC (OR: 4.32). There were no major discerning components associated with mutations. Thus, we conclude that tumor pathology and FH of cancer might be considered together at the time of genetic testing mainly in countries where access to genetic testing is still restricted.
机译:确定遗传性乳腺癌(BC)的高风险家庭非常重要,因为受影响的个体比普通人群呈现出更高的癌症风险。这项研究的目的是确定与致病突变有关的最重要因素。比较了具有致病性变异的卑诗省妇女的家族史(FH),组织病理学和免疫组化特征。 B中的VUS;和零星的卑诗省。观察到的最显着差异涉及肿瘤的分子亚型,癌症诊断时的年龄和癌症的FH。双侧乳腺癌(BBC)的存在,BC例数和卵巢癌(OC)的发生率分别是突变携带者的风险的5.797、5.033和4.412倍。此外,具有或突变的女性表现出不同的肿瘤和FH特征。与突变相关的主要特征是三阴性(OR:17.31),BBC历史(OR:4.96)和OC的出现(OR:4.32)。没有与突变相关的主要识别成分。因此,我们得出结论,在进行基因检测时,主要是在仍然无法获得基因检测的国家中,可以将肿瘤病理学和癌症的FH一起考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号